Primary Hypertension
Conditions
Interventions
Experimental group:Each patient will orally take one tablet of Azilsartan / Amlodipine (240mg Azilsartan + 5mg Amlodipine) daily for 12 consecutive weeks.
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Be between the ages of 18 and 75, regardless of gender. 2. Has been diagnosed with essential hypertension with SBP >=140 mmHg, or DBP>=90 mmHg at baseline in a sitting position. 3. Previous treatment with other antihypertensive drugs with poor or unstable blood pressure control. 4. Signed informed consent and willing to comply with the trial protocol, able to accept follow-up and examination on time. 5. No serious organ function impairment or other diseases that may affect the test results.
Exclusion criteria
Exclusion criteria: 1. Patients who are allergic to alisartan cilexetil, amlodipine or other ingredients. 2. Pregnant and lactating women or women planning to become pregnant. 3. Patients with severe cardiovascular and cerebrovascular events (such as myocardial infarction, stroke) or severe heart diseases such as unstable angina pectoris and heart failure in the past 6 months. 4. Patients with severe hepatic or renal insufficiency. 5. Patients who are using drugs (such as corticosteroids, immunosuppressants) that may affect blood pressure or interfere with the efficacy of the trial drug, and cannot be discontinued. 6. Patients with a history of severe mental illness or who are receiving relevant treatment. 7. In the opinion of the investigator, it is impossible to complete the entire trial process or other conditions that may affect the results of the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean systolic and mean diastolic blood pressure in a quiet sitting position;Changes in blood pressure during the day, night, and early morning under 24-hour ambulatory blood pressure monitoring; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure rebound during the drug-washout period;Changes in uric acid levels;Incidence of adverse reactions during drug treatment and washout period; | — |
Countries
China
Contacts
Public ContactZhou Xin
Tianjin Medical University General Hospital
Outcome results
None listed